Working… Menu

Comparing the Efficacy and Safety of Biosimilar Candidate Xlucane Versus Lucentis® in Patients With nAMD (XPLORE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03805100
Recruitment Status : Recruiting
First Posted : January 15, 2019
Last Update Posted : July 1, 2020
Stada Arzneimittel AG
Information provided by (Responsible Party):
Xbrane Biopharma AB

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : November 2020
Estimated Study Completion Date : December 2021